The pharmacology and clinical use of caspofungin

William W. Hope, Shmuel Shoham, Thomas J. Walsh

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Caspofungin was the first echinocandin to be licensed for the treatment of invasive fungal infections. Caspofungin has in vitro and in vivo activity against Candida spp. and Aspergillus spp., which constitute the majority of medically important opportunistic fungal pathogens. Caspofungin inhibits the synthesis of the 1,3-β-glucan, with resultant osmotic instability and lysis. The pharmacology of caspofungin is relatively complex. Trafficking of drug into tissues is an important determinant of the shape of the concentration-time relationship. Caspofungin has demonstrated efficacy in experimental models of invasive candidiasis and aspergillosis, which reflect its activity in the treatment of oropharyngeal, esophageal and disseminated candidiasis, as well as salvage therapy for patients with invasive aspergillosis.

Original languageEnglish (US)
Pages (from-to)263-274
Number of pages12
JournalExpert Opinion on Drug Metabolism and Toxicology
Issue number2
StatePublished - Apr 2007
Externally publishedYes


  • Aspergillus
  • Candida
  • Caspofungin
  • Echinocandin
  • Glucan
  • Pharmacodynamics
  • Pharmacokinetics

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology


Dive into the research topics of 'The pharmacology and clinical use of caspofungin'. Together they form a unique fingerprint.

Cite this